Transcriptional control of adenosine signaling by hypoxia-inducible transcription factors during ischemic or inflammatory disease
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Inflammatory lesions, ischemic tissues, or solid tumors are characterized by the occurrence of severe tissue hypoxia within the diseased tissue. Subsequent stabilization of hypoxia-inducible transcription factors—particularly of hypoxia-inducible factor 1α (HIF1A)—results in significant alterations of gene expression of resident cells or inflammatory cells that have been recruited into such lesions. Interestingly, studies of hypoxia-induced changes of gene expression identified a transcriptional program that promotes extracellular adenosine signaling. Adenosine is a signaling molecule that functions through the activation of four distinct adenosine receptors—the ADORA1, ADORA2A, ADORA2B, and ADORA3 receptors. Extracellular adenosine is predominantly derived from the phosphohydrolysis of precursor nucleotides, such as adenosine triphosphate or adenosine monophosphate. HIF1A-elicited alterations in gene expression enhance the enzymatic capacity within inflamed tissues to produce extracellular adenosine. Moreover, hypoxia-elicited induction of adenosine receptors—particularly of ADORA2B—results in increased signal transduction. Functional studies in genetic models for HIF1A or adenosine receptors implicate this pathway in an endogenous feedback loop that dampens excessive inflammation and promotes injury resolution, while at the same time enhancing ischemia tolerance. Therefore, pharmacological strategies to enhance HIF-elicited adenosine production or to promote adenosine signaling through adenosine receptors are being investigated for the treatment of acute inflammatory or ischemic diseases characterized by tissue hypoxia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735 · cited 1×
“This second hydroxylation step facilitates binding of the von Hippel–Lindau gene product, thereby promoting ubiquitination and subsequent proteasomal degradation of HIF1A or HIF2A [41–44].”
BackgroundHypoxia-inducible factors in physiology and medicine
Semenza, G. L. (2012) · Cell · doi:10.1016/j.cell.2012.01.021 · Cited by 3,645
Epstein, A. C. R., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00507-4 · Cited by 3,333
The immunology of stroke: from mechanisms to translation
Iadecola, C., & Anrather, J. (2011) · Nature Medicine · doi:10.1038/nm.2399 · Cited by 2,596 · cited 1×
“For example, ischemic tissue injury—such as that occurring in the context of myocardial infarction [15, 16], acute kidney injury (AKI) [17], or stroke [18]—is characterized by a profound increase in tissue hypoxia due to lack of arterial supply with oxygen from the blood [7, 19].”
BackgroundEltzschig, H. K., & Carmeliet, P. (2011) · New England Journal of Medicine · doi:10.1056/nejmra0910283 · Cited by 2,061
Self-citationThe “no-reflow” phenomenon after temporary coronary occlusion in the dog
Kloner, R. A., Ganote, C. E., & Jennings, R. B. (1974) · Journal of Clinical Investigation · doi:10.1172/jci107898 · Cited by 1,842 · cited 1×
“In some instances, this can be due to a postischemic no-reflow phenomenon [17, 21–23].”
BackgroundDefining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics
Semenza, G. L. (2010) · Oncogene · doi:10.1038/onc.2009.441 · Cited by 1,712
Mahon, P. C., Hirota, K., & Semenza, G. L. (2001) · Genes & Development · doi:10.1101/gad.924501 · Cited by 1,385
Integration of Oxygen Signaling at the Consensus HRE
Wenger, R. H., Stiehl, D. P., & Camenisch, G. (2005) · Science's STKE · doi:10.1126/stke.3062005re12 · Cited by 1,032
Ryan, S., Taylor, C. T., & McNicholas, W. T. (2005) · Circulation · doi:10.1161/circulationaha.105.556746 · Cited by 970
Interdependence of hypoxic and innate immune responses
Nizet, V., & Johnson, R. S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2607 · Cited by 708 · cited 1×
“Other diseases characterized by tissue hypoxia include infections with pathogens [28–31], cancer [32–34], and obesity [35].”
BackgroundEpithelial hypoxia-inducible factor-1 is protective in murine experimental colitis
Karhausen, J., Furuta, G. T., Tomaszewski, J. E., Johnson, R. S., Colgan, S. P., & Haase, V. H. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200421086 · Cited by 655
Clambey, E. T., McNamee, E. N., Westrich, J. A., Glover, L. E., Campbell, E. L., Jedlicka, P., de Zoeten, E. F., Cambier, J. C., Stenmark, K. R., Colgan, S. P., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1202366109 · Cited by 560 · cited 1×
“Similar to intestinal inflammation, intestinal ischemia is characterized by profound intestinal tissue hypoxia in the context of intermittent loss of perfusion to the gut, resulting in dramatic increases in morbidity and mortality [103].”
BackgroundSelf-citationRegulation of immune cells by local-tissue oxygen tension: HIF1α and adenosine receptors
Sitkovsky, M., & Lukashev, D. (2005) · Nature Reviews Immunology · doi:10.1038/nri1685 · Cited by 518
Coordinated Adenine Nucleotide Phosphohydrolysis and Nucleoside Signaling in Posthypoxic Endothelium
Eltzschig, H. K., Ibla, J. C., Furuta, G. T., Leonard, M. O., Jacobson, K. A., Enjyoji, K., Robson, S. C., & Colgan, S. P. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030891 · Cited by 499 · cited 2×
“Comparative studies of adenosine receptor expression revealed that ADORA2B is selectively induced in different tissues during inflammation or hypoxia, including vascular endothelia [68], intestinal epithelia [66, 72–74], the kidneys [17, 70], the heart [15, 16, 69], and the lungs [86].”
BackgroundSelf-citationHypoxia: an alarm signal during intestinal inflammation
Colgan, S. P., & Taylor, C. T. (2010) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.39 · Cited by 461 · cited 1×
“For example, studies from the laboratory of Sean Colgan have revealed that the inflamed intestinal mucosa becomes severely hypoxic during experimentally induced colitis—an animal model for inflammatory bowel disease [10, 24–26].”
BackgroundThe Hydroxylase Inhibitor Dimethyloxalylglycine Is Protective in a Murine Model of Colitis
Cummins, E. P., Seeballuck, F., Keely, S. J., Mangan, N. E., Callanan, J. J., Fallon, P. G., & Taylor, C. T. (2008) · Gastroenterology · doi:10.1053/j.gastro.2007.10.012 · Cited by 407 · cited 1×
“Interestingly, genetic studies on the role of HIF uncovered that stabilization of HIF provides a protective and anti-inflammatory pathway during intestinal inflammation [10, 11, 25, 95–97].”
BackgroundMucosal Protection by Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibition
Robinson, A., Keely, S., Karhausen, J., Gerich, M. E., Furuta, G. T., & Colgan, S. P. (2008) · Gastroenterology · doi:10.1053/j.gastro.2007.09.033 · Cited by 368
Interdependent roles for hypoxia inducible factor and nuclear factor‐κB in hypoxic inflammation
Taylor, C. T. (2008) · The Journal of Physiology · doi:10.1113/jphysiol.2008.157669 · Cited by 354
Inhibition of oxygen sensors as a therapeutic strategy for ischaemic and inflammatory disease
Fraisl, P., Aragonés, J., & Carmeliet, P. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2761 · Cited by 326 · cited 1×
“Research stimulated by the discovery of HIF1A subsequently identified the molecular pathway that promotes hypoxiaelicited alterations of gene expression [3–5, 8, 36].”
BackgroundEckle, T., Hartmann, K., Bonney, S., Reithel, S., Mittelbronn, M., Walker, L. A., Lowes, B. D., Han, J., Borchers, C. H., Buttrick, P. M., et al. (2012) · Nature Medicine · doi:10.1038/nm.2728 · Cited by 314 · cited 4×
“Comparative studies of adenosine receptor expression revealed that ADORA2B is selectively induced in different tissues during inflammation or hypoxia, including vascular endothelia [68], intestinal epithelia [66, 72–74], the kidneys [17, 70], the heart [15, 16, 69], and the lungs [86].”
BackgroundInfluentialSelf-citationHypoxia and gastrointestinal disease
Taylor, C. T., & Colgan, S. P. (2007) · Journal of Molecular Medicine · doi:10.1007/s00109-007-0277-z · Cited by 313
Friedman, D. J., Künzli, B. M., A-Rahim, Y. I., Sevigny, J., Berberat, P. O., Enjyoji, K., Csizmadia, E., Friess, H., & Robson, S. C. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902869106 · Cited by 284 · cited 1×
“As such, several studies show that mice with failure to produce extracellular adenosine (CD39orCD73mice) develop a more severe course of disease when exposed to experimentally induced inflammatory bowel disease [98, 99].”
BackgroundHypoxia-independent activation of HIF-1 by enterobacteriaceae and their siderophores
Hartmann, H., Eltzschig, H. K., Wurz, H., Hantke, K., Rakin, A., Yazdi, A. S., Matteoli, G., Bohn, E., Autenrieth, I. B., Karhausen, J., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2007.12.008 · Cited by 143 · cited 1×
“In addition to hypoxia-dependent stabilization of HIF, there are also examples of hypoxia-independent HIF stabilization during inflammatory or infectious diseases [28, 29].”
BackgroundSelf-citation
Cited by
Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function
Vigano, S., Alatzoglou, D., Irving, M., Ménétrier-Caux, C., Caux, C., Romero, P., & Coukos, G. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00925 · Cited by 420
Hypoxia signaling in human diseases and therapeutic targets
Lee, J. W., Ko, J., Ju, C., & Eltzschig, H. K. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0235-1 · Cited by 384
Self-citationBorea, P. A., Gessi, S., Merighi, S., & Varani, K. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.02.006 · Cited by 311
Immunosuppressive Activities of Adenosine in Cancer
Allard, B., Beavis, P. A., Darcy, P. K., & Stagg, J. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.04.001 · Cited by 292
Targeting hypoxia-inducible factors: therapeutic opportunities and challenges
Yuan, X., Ruan, W., Bobrow, B., Carmeliet, P., & Eltzschig, H. K. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00848-6 · Cited by 245
“Besides PT2385 and belzutizan, several other small-molecule HIF2α inhibitors from Nikang (NKT2152), Novartis (DFF332) and Arcus (AB521) are in various stages of clinical development (Table 5).”
Self-citation
Metadata
- Authors
- Poth, J. M., Brodsky, K., Ehrentraut, H., Grenz, A., & Eltzschig, H. K.
- Venue
- Journal of Molecular Medicine
- Published
- 2012-12-21
- Volume
- 91
- Issue
- 2
- Pages
- 183-193
- ISSN
- 0946-2716 (ISSN-L)
- 1432-1440
- OpenAlex
- W2032169621
- Cited by
- 120
- References
- 24
- FWCI
- 3.57
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.